title: Thalidomide and sensory neurotoxicity: a neurophysiological study.
abstract: BACKGROUND
  Recent studies confirmed a high incidence of sensory axonal neuropathy in patients treated with different doses of thalidomide. The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.
  
  
  METHODS
  Clinical and electrophysiological data in 12 female patients with CLE during treatment with thalidomide and up to 47 months after discontinuation of treatment were analysed. Sural nerve SAP amplitude reduction > or =40% was the criteria for discontinuing therapy.
  
  
  RESULTS
  During treatment, 11 patients showed a reduction in sural nerve SAP amplitude compared to baseline values (9 with a reduction > or =50% and 2 <50%). One patient showed no changes in SAP amplitude. Five patients complained of paresthesias and leg cramps. After thalidomide treatment, sural SAP amplitude recovered in 3 patients. At detection of reduction in sural nerve SAP amplitude, the median thalidomide cumulative dose was 21.4 g. The threshold neurotoxic dosage is lower than previously reported.
  
  
  CONCLUSIONS
  Sural nerve SAP amplitude reduction is a reliable and sensitive marker of degeneration and recovery of sensory fibres. This electrophysiological parameter provides information about subclinical neurotoxic potential of thalidomide but is not helpful in predicting the appearance of sensory symptoms.
authors.affiliation: Department of Neurosciences, University of Padova, Padova, Italy. gabriella.zara@sanita.padova.it
authors.forename: G
authors.initials: G
authors.lastname: Zara
authors.forename: M
authors.initials: M
authors.lastname: Ermani
authors.forename: R
authors.initials: R
authors.lastname: Rondinone
authors.forename: S
authors.initials: S
authors.lastname: Arienti
authors.forename: A
authors.initials: A
authors.lastname: Doria
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009410:Nerve Degeneration / Q000139:chemically induced; D010146:Pain / Q000175:diagnosis / Q000453:epidemiology; D010147:Pain Measurement; D010292:Paresthesia / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000453:epidemiology; D012678:Sensation Disorders / Q000139:chemically induced* / Q000503:physiopathology; D013497:Sural Nerve / Q000187:drug effects / Q000503:physiopathology; D013792:Thalidomide / Q000009:adverse effects*; D014110:Touch
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide